HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ximelagatran for treatment and prophylaxis of recurrent events in deep vein thrombosis.

Abstract
The treatment of acute venous thromboembolism and prophylaxis of recurrent events with heparin/low molecular weight heparin followed by vitamin K antagonists is limited by several factors. Oral direct thrombin inhibitors (ODTIs) showed a better pharmacological activity and might be an alternative in the treatment of venous thromboembolism. The Thrombin Inhibition in Venous Thromboembolism (THRIVE) program performed some studies developing the ODTI ximelagatran for this indication, and it is presented in the overview. The aim of the THRIVE I study was the dose finding, and that of the THRIVE IV study the applicability in hemodynamic stabile pulmonary embolism. A prospective, randomized, double blind trial was performed to compare oral ximelagatran with enoxaparin/warfarin for a 6-month treatment of acute venous thrombosis (THRIVE II and V). A second double blind study compared ximelagatran with placebo over 18 months after a 6-month anticoagulant therapy of acute deep vein thrombosis. The efficacy and safety of treatment of patients with acute deep venous thrombosis who received 2 infinity 36 mg ximelagatran was not inferior to that of patients who received a conventional anticoagulant for prophylaxis of recurrent events over 6 months. Ximelagatran 2 infinity 24 mg significantly reduced recurrent thromboembolic events compared to placebo without increasing the risk for hemorrhage. A reversible symptomless increase of alanine aminotransferase occurs in 6% to 9.6% of patients between months 2 and 4. The results of the follow-up studies suggest that thromboembolic events may recur in patients with acute venous thromboembolism after termination of treatment with both vitamin K antagonists and ximelagatran.
AuthorsJ Koscielny, H Kiesewetter, I Jörg, J Harenberg
JournalClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis (Clin Appl Thromb Hemost) Vol. 13 Issue 3 Pg. 299-307 (Jul 2007) ISSN: 1076-0296 [Print] United States
PMID17636192 (Publication Type: Journal Article, Review)
Chemical References
  • Anticoagulants
  • Azetidines
  • Benzylamines
  • ximelagatran
  • Alanine Transaminase
  • Thrombin
Topics
  • Alanine Transaminase (blood)
  • Anticoagulants (administration & dosage, pharmacokinetics, therapeutic use)
  • Azetidines (administration & dosage, pharmacokinetics, therapeutic use)
  • Benzylamines (administration & dosage, pharmacokinetics, therapeutic use)
  • Double-Blind Method
  • Humans
  • International Normalized Ratio
  • Prospective Studies
  • Pulmonary Embolism (prevention & control)
  • Randomized Controlled Trials as Topic
  • Recurrence
  • Thrombin (antagonists & inhibitors)
  • Venous Thrombosis (prevention & control)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: